FDA OKs libido-boosting pill for women who have gone through menopause

The FDA is contemplating a change in regulations that would reduce the frequency of warning labels on dietary supplements, a decision that experts warn could lead to consumers overlooking important safety information. This potential rule change reflects ongoing discussions about the adequacy of current labeling practices in the dietary supplement industry.

FDA Commissioner Martin Makary addressed the growing public mistrust in government health advice, particularly regarding vaccine policies and decisions made during the COVID-19 pandemic. He emphasized the need for transparency and accountability in health communications to restore confidence among the public.

Sanofi's shares have declined following a U.S. regulatory decision to delay the approval of tolebrutinib, a drug intended for treating multiple sclerosis. This setback comes as a late-stage trial for a different form of the disease failed to meet its primary endpoint.